Document is current
Any future updates will be listed below
-
Authors
Frank-Publig, Sophie https://orcid.org/0009-0008-1848-2606
Birner, Klaudia
Riedl, Sophie https://orcid.org/0000-0003-0003-0886
Reiter, Gregor S. https://orcid.org/0000-0001-7661-4015
Schmidt-Erfurth, Ursula https://orcid.org/0000-0002-7788-7311
- License Information
-
More Information
Article History
Received: 12 April 2024
Revised: 10 September 2024
Accepted: 4 November 2024
First Online: 18 November 2024
Competing interests
: SF, KB, SR: No financial disclosures. GSR: Apellis (C), Bayer (C), RetInSight (F), Roche (C), Boehringer Ingelheim (C). US-E: Abbvie (C), Apellis Pharmaceuticals (F, C), Aviceda (C), Complement therapeutics (C), Galimedix (C), Genentech (F), Janssen (C), Heidelberg Engineering (C, F), Kodiak (F), Kriya (C), Novartis (F), ONL (C), Roche (C, F), RetInSight (C), Stealth Therapeutics (C), Topcon (F, C).
